1 March 2020 - The March 2020 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The March issue of the Schedule includes several new listings:

• Atezolizumab (Tecentriq) - new indication
• Budesonide with eformoterol fumarate dihydrate (Symbicort Turbuhaler, Symbicort Rapihaler) - new indication
• Cladribine (Mavenclad) - restriction change
• Dimethyl fumarate (Tecfidera) - restriction change
• Durvalumab (Imfinzi) - new medicine
• Fingolimod hydrochloride (Gilenya) - restriction change
• Glycomacropeptide with essential amino acids and vitamins and minerals (TYR Sphere 20) - new formulation
• Isotretinoin (Oratane) - new strength
• Ipilimumab (Yervoy) - new indication
• Levodopa with carbidopa (Duodopa) - restriction change
• Levonorgestel (Kyleena) - new formulation
• Nivolumab (Opdivo) - new indication
• Pegfilgrastim (Ziextenzo) - new biosimilar medicine
• Prednisolone acetate with phenylephrine hydrochloride (Prednefrin Forte) - new indication
• Tacrolimus monohydrate (Advagraf XL) - new strength
• Teriflunomide (Aubagio) - restriction change

Read Summary of PBS Changes